United States Army Medical Materiel Agency

Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Products to Treat Tropical Diseases

Retrieved on: 
Monday, July 31, 2023
Q fever, Regulated Activation Networks, United States Army Medical Materiel Agency, Tularemia, Licensure, United States Army Medical Research and Development Command, Chikungunya, Investigational New Drug, Venezuelan equine encephalitis virus, United States Department of the Army, Government, Rift Valley fever, Disease, Pharmaceutical industry, Defender

Medical Research and Development Command (USAMRDC), to develop and commercialize a total of eight products for use against the following tropical diseases: tularemia (rabbit virus); Venezuelan Equine Encephalitis (two formulations); Eastern Equine Encephalitis; Western Equine Encephalitis; Rift Valley Fever; chikungunya and Q Fever.

Key Points: 
  • Medical Research and Development Command (USAMRDC), to develop and commercialize a total of eight products for use against the following tropical diseases: tularemia (rabbit virus); Venezuelan Equine Encephalitis (two formulations); Eastern Equine Encephalitis; Western Equine Encephalitis; Rift Valley Fever; chikungunya and Q Fever.
  • The agreement was entered into on July 25th, 2023 and covers eight investigational vaccines that have been part of the Army’s Special Immunization Program.
  • Under the agreement, USAMMDA will transfer the Investigational New Drug applications for each of the eight products, related data, and biological materials to Defender.
  • Development work on these products will commence once this transfer is complete.

Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD)

Retrieved on: 
Wednesday, May 10, 2023
Hallucination, Defense Health Agency, Partnership, Central nervous system, Depression, Cataplexy, CIV, Office of Inspector General, U.S. Department of Health and Human Services, Medication, Tell, Suicide, Sleep paralysis, Drug discovery, United States Army Medical Materiel Agency, U.S. Department of Defense Strategy for Operating in Cyberspace, DORA, Sleep, Clinical trial, QUVIVIQ, Woman, DSM-IV codes, Sleep apnea, Medicine, Veteran, Idorsia, Trial of the century, Lung, Thought, Herbal, Muscle weakness, DOD, Insomnia, Vitamin, Investigational New Drug, European, Somnolence, FDA, Post-traumatic stress disorder, Headache, PTSD, Safety, Full, Complex, Dietary supplement, Pharmaceutical industry, Nursing, Liquor, Residential care, Mail order, Defense

The clinical trial is expected to enroll its first subject in Q2 2023, and the QUVIVIQ arm of the study is forecast to run for approximately three years.

Key Points: 
  • The clinical trial is expected to enroll its first subject in Q2 2023, and the QUVIVIQ arm of the study is forecast to run for approximately three years.
  • USAMMDA is working on behalf of the Defense Health Agency to administer the trial.
  • "We'll efficiently test multiple potential treatments for PTSD and significantly contribute to the development of new safe and effective therapies."
  • For more information about QUVIVIQ, see the Full Prescribing Information and Medication Guide
    QUVIVIQ may cause serious side effects, including:
    Decreased awareness and alertness.

Q30 Innovations is Awarded $2.8 Million Contract by the US Army Medical Research Acquisition Activity to Aid in the Fight Against Traumatic Brain Injury in the Military

Retrieved on: 
Wednesday, October 26, 2022
Acceleration, Engineering, Q30, Safety, Association, Brain, Risk, Skull, De novo, TBI, United States Army Medical Materiel Agency, Brain damage, Method, Traumatic brain injury, Improvised explosive device, Ageing, Research, Woman, GLOBE, United States Army Medical Research and Development Command, Marketing, FDA, Sport, Classification, United States Department of Defense, Neuron, Athlete, Football, Medical device, Medical imaging, Pharmaceutical industry, Collar

The awarded contract enables further research and development to study the safety, efficacy, and field suitability of the Q-Collar in operational scenarios to include blast.

Key Points: 
  • The awarded contract enables further research and development to study the safety, efficacy, and field suitability of the Q-Collar in operational scenarios to include blast.
  • "The Q-Collar is a proven device to help mitigate the risks of brain injuries caused by head impacts.
  • On the sports field and potentially the battlefield, the Q-Collar is protective gear specifically designed to help safeguard the brain.
  • Based in Westport, Connecticut, Q30 Innovations' mission is to help protect the brain from the effects of head impacts on the sports field and the battlefield.

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Retrieved on: 
Thursday, August 11, 2022
Knowledge, FDA, Death, Biomarker, The Lancet, NYSE, United States Department of Defense, United States Army Medical Research and Development Command, Ubiquitin, Neuron, Brain, CT, Transformative research, Disability, Research, Life, Blood, Probability, Plasma, Ubiquitin carboxy-terminal hydrolase L1, U.S. Department of Defense Strategy for Operating in Cyberspace, Patient, Prognosis, Twitter, Glial fibrillary acidic protein, National Health and Nutrition Examination Survey, GFAP, Mark (given name), United States Army Medical Materiel Agency, EDTA, University, Aline Miller, Emergency medicine, Head, Protein, United States Army Medical Research Institute of Infectious Diseases, LinkedIn, Neurology, Traumatic brain injury, Medical device, Medical imaging, TBI

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.

Key Points: 
  • Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.
  • The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury.
  • Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.
  • More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html
    The i-STAT Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results.

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Retrieved on: 
Thursday, August 11, 2022
Knowledge, FDA, Death, Biomarker, The Lancet, NYSE, United States Department of Defense, United States Army Medical Research and Development Command, Ubiquitin, Neuron, Brain, CT, Transformative research, Disability, Research, Life, Blood, Probability, Plasma, Ubiquitin carboxy-terminal hydrolase L1, U.S. Department of Defense Strategy for Operating in Cyberspace, Patient, Prognosis, Twitter, Glial fibrillary acidic protein, National Health and Nutrition Examination Survey, GFAP, Mark (given name), United States Army Medical Materiel Agency, EDTA, University, Aline Miller, Emergency medicine, Head, Protein, United States Army Medical Research Institute of Infectious Diseases, LinkedIn, Neurology, Traumatic brain injury, Medical device, Medical imaging, TBI

Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.

Key Points: 
  • Researchers measured levels of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1) present in blood plasma within 24 hours of injury.
  • The researchers found that high values of the biomarkers, GFAP and UCH-L1, correlate with death and severe injury.
  • Test results are available approximately 15 minutes after a plasma sample is inserted in the test i-STAT cartridge.
  • More information is available at www.globalpointofcare.abbott/en/product-details/apoc/istat-tbi-plasma.html
    The i-STAT Alinity is an easy-to-use, portable blood analyzer that delivers real-time, lab-quality diagnostic test results.

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

Retrieved on: 
Tuesday, August 2, 2022
Research, Other Defense, Infectious Diseases, Biotechnology, General Health, Pharmaceutical, Health, Science, Defense, Other Science, TSX, Infection, Social stigma, Leishmaniasis, Defense, Universidad, CL, Cutaneous leishmaniasis, Woman, Research, Intention, Scar, Therapy, Ulcer, Safety, News, Hospital, United States Army Medical Materiel Agency, Drug development, Company, Patient, Skin infection, Death, Growth, Leishmania, U.S. Department of Defense Strategy for Operating in Cyberspace, OTCQX, Pharmaceutical industry, M.D

Presentation details for Appili are as follows:

Key Points: 
  • Presentation details for Appili are as follows:
    Location: Programa de Estudio y Control de Enfermedades Tropicales of the Universidad de Antioquia, Colombia
    Appili management will also be conducting in-person meetings throughout the conference.
  • To request a meeting, please register for the conference here .
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.

AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and Veterans

Retrieved on: 
Tuesday, July 12, 2022
Defense, Veteran, United States Army Futures Command, Precision medicine, Anxiety, Speech disorder, APTS, Product manager, National Defense Strategy (United States), Compliance, Course Correction, Diagnosis, Medicine, Vaccine, Artificial intelligence, Multimedia, Psychiatry, Service, Combat support agency, Comorbidity, Survival, United States Army Medical Research and Development Command, Digital, Defense Health Agency, Patient, CEO, Digital health, NEW, Program, NIH, Depression, Time, National, APT, United States Army Medical Materiel Agency, Health, AI, FDA, Quality of life, Research, Unified combatant command, Military Health System, Post-traumatic stress disorder, DHA, Biomarker, Pharmaceutical industry, Medical device, PTSD, School of Advanced Warfighting

By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.

Key Points: 
  • By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.
  • Eighty percent have at least one additional comorbidity such as depression, anxiety or substance abuse disorder, complicating diagnosis and treatment further1.
  • Despite the societal, financial, and emotional strain that PTSD exerts upon patients, treatment options remain scarce, with only two FDA approved therapies.
  • DHA supports the National Defense Strategy and Service Military Departments by leading the Military Health System as an integrated, highly-reliable system of readiness, medical training, and health.

Trauma Triage Treatment and Training Decision Support (4TDS)

Retrieved on: 
Friday, June 10, 2022
Amos, Science, Navy, Army, Vital signs, Internal bleeding, Research, Transport, Doctor of Philosophy, United States Army Medical Research and Development Command, Joint Base San Antonio, Air force, Artificial intelligence, United States Army Medical Materiel Agency, Outline of health sciences, TCCC, Tactical Combat Casualty Care, Bleeding, Trauma, Probability, Nursing, Solution, Uniformed Services University of the Health Sciences, Biomedical engineering, Systems analysis, FDA, Triage, Training, Poi, Disease, Mortality, Risk, Biotechnology, USUHS, Shock, Diagnosis, MD, Oxygen saturation (medicine), Pacific Northwest National Laboratory, ARA, Engineering, PFC, Health, Mayo Clinic, Clinical professor, JBSA, Medical device

To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.

Key Points: 
  • To meet that need, Applied Research Associates, Inc. (ARA), the Mayo Clinic, and Ambient Clinical Analytics developed the Trauma Triage Treatment and Training Decision Support (4TDS) system.
  • Early engagement with experienced military medics and clinicians from all services ensured 4TDS reflects their mental models and work processes.
  • It also built support among potential users should the system transition to operational use.
  • Dr. Herasevich led shock prediction model development and testing with support from ARAs Adam Amos-Binks, PhD.

VaxAlta Inc. Announces License Agreement With Scandinavian Biopharma

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Pharmaceutical, Health, Technology, EDCTP, United States Army Medical Materiel Agency, Sutro Biopharma, Bill & Melinda Gates Foundation, CEO, Canada, Horizon, III, Norton Rose Fulbright, LLP, Antibody, Vinnova, Diarrhea, Vaccine, Research, ETEC, PATH, Science, Partnership, Pharmaceutical industry, EU, VaxAlta Inc., Scandinavian Biopharma Holdings AB, VAXALTA INC., SCANDINAVIAN BIOPHARMA HOLDINGS AB

Under the terms of the agreement, Scandinavian Biopharma and VaxAlta will jointly be responsible for the development of potential vaccine candidates for C. jejuni for human applications, and Scandinavian Biopharma will lead the development, registration and commercialization of any successful vaccine.

Key Points: 
  • Under the terms of the agreement, Scandinavian Biopharma and VaxAlta will jointly be responsible for the development of potential vaccine candidates for C. jejuni for human applications, and Scandinavian Biopharma will lead the development, registration and commercialization of any successful vaccine.
  • Scandinavian Biopharma shall have exclusive global rights for any products using VaxAltas technology in developed countries, and non-exclusive global rights in developing countries.
  • In addition, Scandinavian Biopharma will pay VaxAlta undisclosed royalties on sales of products resulting from the collaboration.
  • Scandinavian Biopharma also distributes a wide range of specialty biopharma products with a focus on vaccines and immunoglobulins.

ERProsource360 Awarded GSA Schedule Medical Logistics Task Order Worth More Than $35M

Retrieved on: 
Wednesday, March 4, 2020
Logistics, Fort Detrick, United States Army Medical Materiel Agency, Medical materiel, Materiel, Medical logistics

WASHINGTON, March 4, 2020 /PRNewswire/ -- ERProsource360, LLC, a joint venture between ERP International, LLC (ERP) and ProSource360 Consulting Services, Inc. (ProSource360), has been awarded a GSA Schedule task order with the US Army Medical Materiel Development Activity (USAMMDA) and US Army Medical Materiel Agency (USAMMA) to perform a wide range of medical logistics, medical materiel management, and medical materiel fielding support services.

Key Points: 
  • WASHINGTON, March 4, 2020 /PRNewswire/ -- ERProsource360, LLC, a joint venture between ERP International, LLC (ERP) and ProSource360 Consulting Services, Inc. (ProSource360), has been awarded a GSA Schedule task order with the US Army Medical Materiel Development Activity (USAMMDA) and US Army Medical Materiel Agency (USAMMA) to perform a wide range of medical logistics, medical materiel management, and medical materiel fielding support services.
  • Under this task order, which totals more than $35 million, ERProsource360 will support all Army components worldwide, with technical and logistical assistance in managing and distributing medical materiel and equipment.
  • ProSource360 provides a variety of healthcare solutions, including clinical and medical staffing (physicians, nurses and technicians) in multiple Medical Treatment Facilities (MTFs).
  • In addition, ProSource360 is a leader and innovator in the area of Medical Device Cybersecurity, Total Exposure Health and Pharmacy Consulting services.